Radioactive Isotope Labeling Services Market

$485M in 2025, scaling to $892M by 2036 on a 5.7% CAGR. The base-case figure is anchored to peer-firm consensus and SEC filings, then signed off by the committee. Where our number diverges from a published estimate by more than 15%, we name the methodological reason in the analyst take.

Quotient Sciences holds 16.1% on roughly $78M of sector revenue. Add PerkinElmer (Revvity Radiochemicals) at 8.7% and Moravek Biochemicals at 7.8% and the top three control 33%. The remaining 67% is split across regional incumbents and a long tail of acquisition candidates for any of the top three.

Direct custom-synthesis contracts (Quotient, Moravek, ViTrax) at 58% of value. The cube spans by drug class / product type / by route of administration / modality / by end user (hospitals, clinics, homecare, research) / by distribution channel, with sub-segment shares anchored to peer-firm breakdowns and committee-reviewed sizing. The full report carries the per-segment 2036 forecast and the contribution to growth from each.

North America ran 41.3% of the 2025 pool, roughly $200M in absolute terms. Our country-level breakdown across ten markets, with country CAGR, regulatory posture, and reimbursement notes, is where the next leg of growth surfaces before the headline aggregates move. That sits in the full report.

Top of our list on the upside: oncology pipeline density, with accelerated ind timelines a close second. The binding constraint over the next twenty-four months is isotope supply chain brittleness. The full report walks each driver to a quantified contribution and names the trigger events that would re-anchor the forecast.

Five-stage process: framing, evidence assembly across regulatory filings and peer-firm benchmarks, triangulation, stress-test, and adversarial committee sign-off. Nothing publishes without the committee. Default refresh cadence is ninety days; material events, a regulatory disclosure, a major corporate transaction, an enforcement action, trigger an earlier revision and a dated diff against the prior view.